DNA β-amyloid1-42 trimer immunization for alzheimer diseaseina wild-type mouse model

Doris Lambracht-Washington, Bao Xi Qu, Min Fu, Todd N. Eagar, Olaf Stüve, Roger N. Rosenberg

Research output: Contribution to journalArticle

40 Citations (Scopus)

Abstract

Context: DNA β-amyloid1-42 (Aβ42) trimer immunization was developed to produce specific T helper 2 cell (TH2)-type antibodies to provide an effective and safe therapy for Alzheimer disease (AD) by reducing elevated levels of Aβ42 peptide that occur in the brain of patients with AD. Objective: To compare the immune response in wild-type mice after immunization with DNA Aβ42 trimer and Aβ42 peptide. Design and Intervention: Wild-type mice received either 4 μ g of DNA Aβ42 trimer immunization administered with gene gun (n=8) or intraperitoneal injection of 100 μ g of human Aβ42 peptide with the adjuvant Quil A (n=8). Titers, epitope mapping, and isotypes of the Aβ42-specific antibodies were analyzed. Main Outcome Measures: Antibody titers, mapping of binding sites (epitopes), isotype profiles of the Aβ42-specific antibodies, and T-cell activation. Results: DNA Aβ42 trimer immunization resulted in antibody titers with a mean of 15 μ g per milliliter of plasma. The isotype profile of the antibodies differed markedly. A predominant IgG1 antibody response was found in the DNA-immunized mice, indicating a TH2 type of immune response (IgG1/IgG2a ratio of 10). The peptideimmunized mice showed a mixed TH1/TH2 immune response (IgG1/IgG2a ratio of 1) (P<.001). No increased T-cell proliferation was observed in the DNA-immunized mice (P=.03). Conclusion: In this preliminary study in a wild-type mouse model, DNA Aβ42 trimer immunization protocol produced a TH2 immune response and appeared to have low potential to cause an inflammatory T-cell response.

Original languageEnglish (US)
Pages (from-to)1796-1802
Number of pages7
JournalJAMA - Journal of the American Medical Association
Volume302
Issue number16
DOIs
StatePublished - 2009

Fingerprint

Immunization
Th2 Cells
DNA
Antibodies
Immunoglobulin G
T-Lymphocytes
Peptides
Alzheimer Disease
Epitope Mapping
Firearms
Intraperitoneal Injections
Antibody Formation
Epitopes
Binding Sites
Cell Proliferation
Outcome Assessment (Health Care)
Brain
Genes

ASJC Scopus subject areas

  • Medicine(all)

Cite this

DNA β-amyloid1-42 trimer immunization for alzheimer diseaseina wild-type mouse model. / Lambracht-Washington, Doris; Qu, Bao Xi; Fu, Min; Eagar, Todd N.; Stüve, Olaf; Rosenberg, Roger N.

In: JAMA - Journal of the American Medical Association, Vol. 302, No. 16, 2009, p. 1796-1802.

Research output: Contribution to journalArticle

@article{503a686472b34a2fb206b176e6ce78e5,
title = "DNA β-amyloid1-42 trimer immunization for alzheimer diseaseina wild-type mouse model",
abstract = "Context: DNA β-amyloid1-42 (Aβ42) trimer immunization was developed to produce specific T helper 2 cell (TH2)-type antibodies to provide an effective and safe therapy for Alzheimer disease (AD) by reducing elevated levels of Aβ42 peptide that occur in the brain of patients with AD. Objective: To compare the immune response in wild-type mice after immunization with DNA Aβ42 trimer and Aβ42 peptide. Design and Intervention: Wild-type mice received either 4 μ g of DNA Aβ42 trimer immunization administered with gene gun (n=8) or intraperitoneal injection of 100 μ g of human Aβ42 peptide with the adjuvant Quil A (n=8). Titers, epitope mapping, and isotypes of the Aβ42-specific antibodies were analyzed. Main Outcome Measures: Antibody titers, mapping of binding sites (epitopes), isotype profiles of the Aβ42-specific antibodies, and T-cell activation. Results: DNA Aβ42 trimer immunization resulted in antibody titers with a mean of 15 μ g per milliliter of plasma. The isotype profile of the antibodies differed markedly. A predominant IgG1 antibody response was found in the DNA-immunized mice, indicating a TH2 type of immune response (IgG1/IgG2a ratio of 10). The peptideimmunized mice showed a mixed TH1/TH2 immune response (IgG1/IgG2a ratio of 1) (P<.001). No increased T-cell proliferation was observed in the DNA-immunized mice (P=.03). Conclusion: In this preliminary study in a wild-type mouse model, DNA Aβ42 trimer immunization protocol produced a TH2 immune response and appeared to have low potential to cause an inflammatory T-cell response.",
author = "Doris Lambracht-Washington and Qu, {Bao Xi} and Min Fu and Eagar, {Todd N.} and Olaf St{\"u}ve and Rosenberg, {Roger N.}",
year = "2009",
doi = "10.1001/jama.2009.1547",
language = "English (US)",
volume = "302",
pages = "1796--1802",
journal = "JAMA - Journal of the American Medical Association",
issn = "0098-7484",
publisher = "American Medical Association",
number = "16",

}

TY - JOUR

T1 - DNA β-amyloid1-42 trimer immunization for alzheimer diseaseina wild-type mouse model

AU - Lambracht-Washington, Doris

AU - Qu, Bao Xi

AU - Fu, Min

AU - Eagar, Todd N.

AU - Stüve, Olaf

AU - Rosenberg, Roger N.

PY - 2009

Y1 - 2009

N2 - Context: DNA β-amyloid1-42 (Aβ42) trimer immunization was developed to produce specific T helper 2 cell (TH2)-type antibodies to provide an effective and safe therapy for Alzheimer disease (AD) by reducing elevated levels of Aβ42 peptide that occur in the brain of patients with AD. Objective: To compare the immune response in wild-type mice after immunization with DNA Aβ42 trimer and Aβ42 peptide. Design and Intervention: Wild-type mice received either 4 μ g of DNA Aβ42 trimer immunization administered with gene gun (n=8) or intraperitoneal injection of 100 μ g of human Aβ42 peptide with the adjuvant Quil A (n=8). Titers, epitope mapping, and isotypes of the Aβ42-specific antibodies were analyzed. Main Outcome Measures: Antibody titers, mapping of binding sites (epitopes), isotype profiles of the Aβ42-specific antibodies, and T-cell activation. Results: DNA Aβ42 trimer immunization resulted in antibody titers with a mean of 15 μ g per milliliter of plasma. The isotype profile of the antibodies differed markedly. A predominant IgG1 antibody response was found in the DNA-immunized mice, indicating a TH2 type of immune response (IgG1/IgG2a ratio of 10). The peptideimmunized mice showed a mixed TH1/TH2 immune response (IgG1/IgG2a ratio of 1) (P<.001). No increased T-cell proliferation was observed in the DNA-immunized mice (P=.03). Conclusion: In this preliminary study in a wild-type mouse model, DNA Aβ42 trimer immunization protocol produced a TH2 immune response and appeared to have low potential to cause an inflammatory T-cell response.

AB - Context: DNA β-amyloid1-42 (Aβ42) trimer immunization was developed to produce specific T helper 2 cell (TH2)-type antibodies to provide an effective and safe therapy for Alzheimer disease (AD) by reducing elevated levels of Aβ42 peptide that occur in the brain of patients with AD. Objective: To compare the immune response in wild-type mice after immunization with DNA Aβ42 trimer and Aβ42 peptide. Design and Intervention: Wild-type mice received either 4 μ g of DNA Aβ42 trimer immunization administered with gene gun (n=8) or intraperitoneal injection of 100 μ g of human Aβ42 peptide with the adjuvant Quil A (n=8). Titers, epitope mapping, and isotypes of the Aβ42-specific antibodies were analyzed. Main Outcome Measures: Antibody titers, mapping of binding sites (epitopes), isotype profiles of the Aβ42-specific antibodies, and T-cell activation. Results: DNA Aβ42 trimer immunization resulted in antibody titers with a mean of 15 μ g per milliliter of plasma. The isotype profile of the antibodies differed markedly. A predominant IgG1 antibody response was found in the DNA-immunized mice, indicating a TH2 type of immune response (IgG1/IgG2a ratio of 10). The peptideimmunized mice showed a mixed TH1/TH2 immune response (IgG1/IgG2a ratio of 1) (P<.001). No increased T-cell proliferation was observed in the DNA-immunized mice (P=.03). Conclusion: In this preliminary study in a wild-type mouse model, DNA Aβ42 trimer immunization protocol produced a TH2 immune response and appeared to have low potential to cause an inflammatory T-cell response.

UR - http://www.scopus.com/inward/record.url?scp=70350735909&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=70350735909&partnerID=8YFLogxK

U2 - 10.1001/jama.2009.1547

DO - 10.1001/jama.2009.1547

M3 - Article

C2 - 19861672

AN - SCOPUS:70350735909

VL - 302

SP - 1796

EP - 1802

JO - JAMA - Journal of the American Medical Association

JF - JAMA - Journal of the American Medical Association

SN - 0098-7484

IS - 16

ER -